IP Library › Granted Patent US 12,703,741
Granted Patent B2
US 12,703,741 · App. 17/649,732 · Granted Aug 11, 2026

Treatment of congestive heart failure and other cardiac dysfunction using a GDF15 modulator

Inventors: Jeno Gyuris (Lincoln, MA); Lorena Lerner (Newton Centre, MA)
Assignee: AVEO Pharmaceuticals, Inc.
C07K16/22A61K2039/505C07K2317/24C07K2317/56C07K2317/565C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,703,741
App. No.
17/649,732
Filed
Feb 2, 2022
Granted
Aug 11, 2026
Kind
B2
Art Unit
1674
USPC
424/133.1
Abstract

The invention provides methods and compositions of treating a subject having a cardiac-related disorder such as congestive or chronic heart failure (CHF), cardiac hypertrophy, cardiac hypotrophy, and other cardiac myopathies/dystrophies. The methods comprise administering an effective amount of a composition that modulates, for example, reduces or inhibits, GDF15 activity in the subject.

Claims (27)

1 . A method of treating cardiac hypotrophy in a subject in need thereof, the method comprising administering to the subject an effective amount of an anti-GDF15 antibody selected from the group consisting of

a) an antibody comprising the heavy chain sequence of SEQ ID NO:47 or 49 and the light chain sequence of SEQ ID NO:30;

b) an antibody comprising the heavy chain sequence of SEQ ID NO:41, 42, 43, 44, 45, 46, 48, or 49 and the light chain sequence of SEQ ID NO:29;

c) an antibody comprising the heavy chain sequence of SEQ ID NO:41, 42, 43, 44, or 45 and the light chain sequence of SEQ ID NO:28;

d) an antibody comprising the heavy chain sequence of SEQ ID NO:39, 40, 41, 42, 43, 44, or 45 and the light chain sequence of SEQ ID NO:27;

e) an antibody comprising the heavy chain sequence of SEQ ID NO:38 and the light chain sequence of SEQ ID NO:26;

f) an antibody comprising the heavy chain sequence of SEQ ID NO:37 and the light chain sequence of SEQ ID NO:25;

g) an antibody comprising a heavy chain CDR H1 sequence of SEQ ID NO:1, a heavy chain CDR H2 sequence of SEQ ID NO:7, and a heavy chain CDR H3 sequence of SEQ ID NO:13; and

a light chain CDR L1 sequence of SEQ ID NO:16, a light chain CDR L2 sequence of SEQ ID NO:18, and a light chain CDR L3 sequence of SEQ ID NO:22;

h) an antibody comprising a heavy chain CDR H1 sequence of SEQ ID NO:1, a heavy chain CDR H2 sequence of SEQ ID NO:9, and a heavy chain CDR H3 sequence of SEQ ID NO:13; and

a light chain CDR L1 sequence of SEQ ID NO:16, a light chain CDR L2 sequence of SEQ ID NO:18, and a light chain CDR L3 sequence of SEQ ID NO:22;

i) an antibody comprising a heavy chain CDR H1 sequence of SEQ ID NO:1, a heavy chain CDR H2 sequence of SEQ ID NO:4, and a heavy chain CDR H3 sequence of SEQ ID NO:13; and

a light chain CDR L1 sequence of SEQ ID NO:16, a light chain CDR L2 sequence of SEQ ID NO:18, and a light chain CDR L3 sequence of SEQ ID NO:21;

j) an antibody comprising a heavy chain CDR H1 sequence of SEQ ID NO:1, a heavy chain CDR H2 sequence of SEQ ID NO:5, and a heavy chain CDR H3 sequence of SEQ ID NO:13; and

a light chain CDR L1 sequence of SEQ ID NO:16, a light chain CDR L2 sequence of SEQ ID NO:18, and a light chain CDR L3 sequence of SEQ ID NO:21;

k) an antibody comprising a heavy chain CDR H1 sequence of SEQ ID NO:1, a heavy chain CDR H2 sequence of SEQ ID NO:6, and a heavy chain CDR H3 sequence of SEQ ID NO:13; and

a light chain CDR L1 sequence of SEQ ID NO:16, a light chain CDR L2 sequence of SEQ ID NO:18, and a light chain CDR L3 sequence of SEQ ID NO:21;

l. an antibody comprising a heavy chain CDR H1 sequence of SEQ ID NO:1, a heavy chain CDR H2 sequence of SEQ ID NO:8, and a heavy chain CDR H3 sequence of SEQ ID NO:13; and

a light chain CDR L1 sequence of SEQ ID NO:16, a light chain CDR L2 sequence of SEQ ID NO:18, and a light chain CDR L3 sequence of SEQ ID NO:21; and

m) an antibody comprising a heavy chain CDR H1 sequence of SEQ ID NO:1, a heavy chain CDR H2 sequence of SEQ ID NO:9, and a heavy chain CDR H3 sequence of SEQ ID NO:13; and

a light chain CDR L1 sequence of SEQ ID NO:16, a light chain CDR L2 sequence of SEQ ID NO:18, and a light chain CDR L3 sequence of SEQ ID NO:21,

thereby reducing or inhibiting GDF15 activity in the subject.

2 . The method of claim 1 , wherein the antibody is humanized or human.

3 . The method of claim 1 , wherein the anti-GDF15 antibody comprises the heavy chain sequence of SEQ ID NO:47 and the light chain sequence of SEQ ID NO:30.

4 . The method of claim 1 , wherein the anti-GDF15 antibody comprises a heavy chain CDR H1 sequence of SEQ ID NO:1, a heavy chain CDR H2 sequence of SEQ ID NO:7, and a heavy chain CDR H3 sequence of SEQ ID NO:13; and a light chain CDR L1 sequence of SEQ ID NO:16, a light chain CDR L2 sequence of SEQ ID NO:18, and a light chain CDR L3 sequence of SEQ ID NO:22.

5 . The method of claim 1 , wherein the anti-GDF15 antibody comprises the heavy chain sequence of SEQ ID NO:48 and the light chain sequence of SEQ ID NO:29.

6 . The method of claim 1 , wherein the anti-GDF15 antibody comprises a heavy chain CDR H1 sequence of SEQ ID NO:1, a heavy chain CDR H2 sequence of SEQ ID NO:8, and a heavy chain CDR H3 sequence of SEQ ID NO:13; and a light chain CDR L1 sequence of SEQ ID NO:16, a light chain CDR L2 sequence of SEQ ID NO:18, and a light chain CDR L3 sequence of SEQ ID NO:21.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2022
From: GYURIS, JENO; LERNER, LORENA
To: AVEO PHARMACEUTICALS, INC.
Reel/Frame 060661/0713 →
Continuity (4)
Continuation 16177792 · Nov 1, 2018
Continuation 15320094 · Jun 19, 2015
Provisional Application 62015093 · Jun 20, 2014
Related Publication 20220403015A1 · Dec 22, 2022
References Cited (166)
US 5994102A · Hudson et al. · 1999 [cited by applicant]
US 6051424A · Kato et al. · 2000 [cited by applicant]
US 6180602B1 · Kato et al. · 2001 [cited by applicant]
US 6420543B1 · Lee et al. · 2002 [cited by applicant]
US 6465181B2 · Billing-Medel et al. · 2002 [cited by applicant]
US 6500638B2 · Hudson et al. · 2002 [cited by applicant]
US 6521227B1 · Hudson et al. · 2003 [cited by applicant]
US 7157235B2 · Breit et al. · 2007 [cited by applicant]
US 7282351B2 · Hudson et al. · 2007 [cited by applicant]
US 7514221B2 · Breit et al. · 2009 [cited by applicant]
US 7741055B2 · Hudson et al. · 2010 [cited by applicant]
US 7919084B2 · Breit · 2011 [cited by examiner]
US 7968303B2 · Breit et al. · 2011 [cited by applicant]
US 8173434B2 · Fan et al. · 2012 [cited by applicant]
US 8192735B2 · Breit et al. · 2012 [cited by applicant]
US 9175076B2 · Lerner et al. · 2015 [cited by applicant]
US 9334331B2 · Igawa · 2016 [cited by examiner]
US 9725505B2 · Lerner · 2017 [cited by examiner]
US 10421807B2 · Gonzales · 2019 [cited by examiner]
US 10597444B2 · Lerner et al. · 2020 [cited by applicant]
US 20030232385A1 · Breit et al. · 2003 [cited by applicant]
US 20060263774A1 · Clark et al. · 2006 [cited by applicant]
US 20070207462A1 · Ichinose et al. · 2007 [cited by applicant]
US 20090004181A1 · Breit · 2009 [cited by examiner]
US 20090021293A1 · Hebert et al. · 2009 [cited by applicant]
US 20100266707A1 · Breit · 2010 [cited by examiner]
US 20110033886A1 · Hess et al. · 2011 [cited by applicant]
US 20110065204A1 · Wollert et al. · 2011 [cited by applicant]
US 20110262444A1 · Kim · 2011 [cited by applicant]
US 20110300548A1 · Lambrecht et al. · 2011 [cited by applicant]
US 20120083420A1 · Clark et al. · 2012 [cited by applicant]
US 20140193427A1 · Lerner et al. · 2014 [cited by applicant]
CA 2534871A1 · 2007 [cited by applicant]
EP 1884777A1 · 2008 [cited by applicant]
EP 2047275A2 · 2009 [cited by applicant]
EP 2103943A1 · 2009 [cited by applicant]
WO WO1994003599A1 · 1994 [cited by applicant]
WO WO1996018730A1 · 1996 [cited by applicant]
WO WO1997000958A1 · 1997 [cited by applicant]
WO WO1999006445A1 · 1999 [cited by applicant]
WO WO2000020449A2 · 2000 [cited by applicant]
WO WO2000056352A2 · 2000 [cited by applicant]
WO WO2000070051A1 · 2000 [cited by applicant]
WO WO2002020759A2 · 2002 [cited by applicant]
WO WO2004043385A2 · 2004 [cited by applicant]
WO WO2005044990A2 · 2005 [cited by applicant]
WO WO2005099746A1 · 2005 [cited by applicant]
WO WO2008015254A2 · 2008 [cited by applicant]
WO WO2009021293A1 · 2009 [cited by applicant]
WO WO2009046495A1 · 2009 [cited by applicant]
WO WO2011117254A1 · 2011 [cited by applicant]
WO WO2012113103A1 · 2012 [cited by applicant]
WO WO2014100689A1 · 2014 [cited by applicant]
Feldman, 2002, Molecular Pharmacology. 61(4): 707-709. [cited by examiner]
Janigro (2008, Epilepsy Currents 8(1): 23-24). [cited by examiner]
Kempf et al. (2007, Clin. Chem. 53:284-291). [cited by examiner]
Kempf et al. (2006, Cir. Res. 98:351-360). [cited by examiner]
Xu et al. (2006, Circ. Res. 98:342-350). [cited by examiner]
Tobin et al. (2006, Drug Discovery Today 11:405-411). [cited by examiner]
Lajer et al. (2010, Diabetes Care 33:1567-1572). [cited by examiner]
Al Qaraghuli et al. (2020, Nature Scientific Reports 10:13969). [cited by examiner]
Edwards et al. (2003, JMB 334:103-118). [cited by examiner]
Lloyd et al. (2009, Protein Engineering, Eng. Design & Selection 22(3): 159-168). [cited by examiner]
Goel et al. (2004, J. Immunol. 173: 7358-7367). [cited by examiner]
Khan et al. (2014, J. Immunol. 192: 5398-5405). [cited by examiner]
Poosarla et al. (2017, Biotechn. Bioeng. 114(6): 1331-1342). [cited by examiner]
Rabia, et al. (2018, Biochemical Engineering Journal 137:365-374). [cited by examiner]
Christensen et al., 2013, Endocrine 43:626-634. [cited by examiner]
Klapholz et al. (2004, J. Am. Coll. Cardiol. 43(8):1432-1438). [cited by examiner]
Gradman et al. (2006, Progress in Cardiovascular Disease 48(5):326-341). [cited by examiner]
Montoro-Garcia et al. (2012, Eur. J. Internal Med. 23:169-174). [cited by examiner]
Karavidas et al. (2010, Hellenic J. Cardiol. 51:421-427). [cited by examiner]
Belluardo et al. (2006, Am. J. Physiol. Heart Circ. Physiol. 291:H1529-H1535). [cited by examiner]
Eggers et al. (2008, Eur. Heart J. 29:2252-2258). [cited by examiner]
Zhang et al. (2016, PLoS One 11(6):e0157372; doi:10.1371/journal.pone.0157372; pp. 1-16). [cited by examiner]
Allan et al., “A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats.” J Steroid Biochem Mol Biol. Jan. 2007;103(1):76-83. [cited by applicant]
Argiles et al., “Anti-inflammatory therapies in cancer cachexia.” Eur J Pharmacol. Sep. 2011;668 Suppl 1:S81-6. [cited by applicant]
Baev et al., “Cardiac hypotrophy in young women with low blood pressure,” Biology and Medicine 2014;6(1):1-6. [cited by applicant]
Bauerlein et al., “Efficacy of REGN1033, a fully human anti-myostatin antagonist antibody, in rodent muscle function.” J. Cachexia Sarcopenia Muscle 2013;4:295-343 Abstract 4-06 from 7th Cachexia Conference, Kobe/Osaka,… [cited by applicant]
Baumgartner et al., “Epidemiology of sarcopenia among the elderly in New Mexico.” Am J Epidemiol. Apr. 15, 1998;147(8):755-63. [cited by applicant]
Bauskin et al., “Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer.” Cancer Res. May 15, 2006;66(10):4983-6. [cited by applicant]
Bialek et al., “A myostatin and activin decoy receptor enhances bone formation in mice.” Bone. Mar. 2014; 60:162-171. [cited by applicant]
Bonaca MP et al., (2011), ‘Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome: Observations from Prove It-TIMI 22,’ Anterioscler Thromb Vasc Biol, 31(1):20… [cited by applicant]
Bovee et al., “SERMs and SARMs: detection of their activities with yeast based bioassays.” J. Steroid Biochem. Mol. Biol. 2010;118:85-92. [cited by applicant]
Breit et al. “The TGF-13 superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism” Growth Factors. Oct. 2011;29(5):187-95. [cited by applicant]
Brown DA et al., (2002), ‘Concentration in Plasma of Macrophage Inhibitory Cytokine-1 and Risk of Cardiovascular Events in Women: A Nested Case-Control Study,’ Lancet, 359(9324):2159-63. [cited by applicant]
Cattadori G et al., (2011), ‘Hemodynamic Effects of Exercise Training in Heart Failure,’ J Card Fail, 17(11):916-22. [cited by applicant]
Chen et al., “Discovery and Therpeutic Promise of Selective Androgen Receptor Modulators.” Mol. Interv. Jun. 2005; 5(3):173-188. [cited by applicant]
Clerico A et al., (2012), ‘State of the Art of BNP and NT-proBNP Immunoassays: The CardioOrmoCheck Study,’ Clin Chim Acta, 414:112-9. [cited by applicant]
Dalton et al., “The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled … [cited by applicant]
Davenport and Wright, “Treating Obesity: is it all in the gut?” Drug Discov Today (2013), <http://dx.doi.orp/10.1016/j.drudis.2013.10.025>. [cited by applicant]
DeBoer and Marks, “Cachexia: lessons from melanocortin antagonism.” Trends Endocrinol Metab. Jul. 2006;17(5):199-204. [cited by applicant]
DLibel S et al., ‘Chapter 6: Antibody Affinity,’ Handbook of Therapeutic Antibodies. (2nd Ed, 2010), S DLibel and JM Reichert (eds), Wiley-VCH Verlag GmbH, Weinheim, DE (Pub), pp. 119-144 XP007913671. [cited by applicant]
Enomoto et al., “Suppression of cancer cachexia by 205,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6, receptor antagonist.” Biochem Biophys Res Commun. Oct. 22, 2004;323(3):1096-102. [cited by applicant]
Evans et al., “Cachexia: a new definition.” Clin Nutr. Dec. 2008;27(6):793-9. [cited by applicant]
Faggiano P et al., (1997), ‘Assessment of Oxygen Uptake During the 6-Minute Walking Test in Patients with Heart Failure: Preliminary Experience with a Portable Device,’ Am Heart J, 134(2 Pt 1):203-6. [cited by applicant]
Fairlie et al., “Expression of a TGF-beta superfamily protein, macrophage inhibitory cytokine-1, inthe yeast [cited by applicant]
Fearon et al., “Cancer cachexia: mediators, signaling, and metabolic pathways.” Cell Metab. Aug. 8, 2012;16(2):153-66. [cited by applicant]
Fearon et al., “Definition and classification of cancer cachexia: an international consensus.” Lancet Oncol. May 2011;12(5):489-95. [cited by applicant]
Fong et al. “Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins.” Am J Physiol. Mar. 1989;256(3 Pt 2):R659-65. [cited by applicant]
Foote et al., (1992), “Antibody Framework residues affecting the conformation of the hypervariableloops,” J. Mol. Biol., 224:487-499. [cited by applicant]
Galvani M et al., (1997), ‘Prognostic Influence of Elevated Values of Cardia Troponin I in Patientswith Unstable Angina,’ Circulation, 95(8):2053-9. [cited by applicant]
Glass, “Signaling pathways perturbing muscle mass.” Curr Opin Clin Nutr Metab Care. May 2010;13(3):225-9. [cited by applicant]
Green DJ et al., (2001), ‘A Comparison of the Shuttle and 6 Minute Walking Tests with Measured Peak Oxygen Consumption in Patients with Heart Failure,’ J Sci Med Sport, 4(3):292-300. [cited by applicant]
Guillory et al., “Chapter 3: The Role of Ghrelin in Anorexia-Cachexia Syndromes.” Vitamins and Hormones. 2013; 92:61-106. [cited by applicant]
Heringlake M et al., (2013), ‘Growth Differentiation Factor 15: A Novel Risk Marker Adjunct to the EuroSCORE for Risk Stratification in Cardiac Surgery Patients,’ J Am Col Cardiol, 61(6):672-81. [cited by applicant]
Hinoi et al. “Positive regulation of osteoclastic differentiation by growth differentiation factor 15 upregulated in osteocytic cells under hypoxia” J Bone Miner Res. Apr. 2012;27(4):938-49. [cited by applicant]
Hryniewicz et al., Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. J Card Fail. Dec. 2003;9(6):464-8. [cited by applicant]
International Search Report (Form ISA/210) for Intentional Application No. PCT/US2015/036790 mailed Nov. 30, 2015 (7 pages). [cited by applicant]
Johnen H et al., (2007), ‘Tumor-Induced Anorexia and Weight Loss are Mediated by the TGF-13 Superfamily Cytokine MIC-1,’ Nat Med, 13(11):1333-40. [cited by applicant]
Joppa et al., “Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice.” Peptides. Mar. 2007;28(… [cited by applicant]
Kalinkovich and Livshits, (2015), “Sarcopenia—The search for emerging biomarkers”, Aging Research Reviews, 22:58-71. [cited by applicant]
Kalinkovich et al., “Sarcopenia—The search for emerging biomarkers.” Ageing research reviews vol. 22 (2015): 58-71. [cited by applicant]
Kempf et al. “The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury.” Circulation research vol. 98,3 (2006): 351-60. [cited by applicant]
Kempf T et al., (2006), ‘The Transforming Growth Factor-13 Superfamily Member Growth-Differentiation Factor-15 Protects the Heart from Ischemia/Reperfusion Injury,’ Circ Res, 98(3):351-60. [cited by applicant]
Kempf T et al., (2007), ‘Circulating Concentrations of Growth-Differentiation Factor 15 in Apparently Health Elderly Individuals and Patients with Chronic Heart Failure as Assessed by a New Immunoradiometric Sandwich As… [cited by applicant]
Kempf T et al., (2007), ‘Prognostic Utility of Growth Differentiation Factor-15 in Patients with Chronic Heart Failure,’ J Am Coll Cardiol, 50(11):1054-60. [cited by applicant]
Kempf T et al., (2011), ‘GDF-15 is an Indicator of Leukocyte Integrin Activation Required for Survival and Myocardial Infarction in Mice,’ Nat Med, 17(5):581-8. [cited by applicant]
Lajer et al. “Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy,” Diabetes Car… [cited by applicant]
Lajer M et al., (2010), ‘Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality as well as Deterioration of Kidney Function in Type 1 Diabetic Patients with Nephropathy,’ D… [cited by applicant]
Lanier GM et al., (2012), ‘Simple Prediction Formula for Peak Oxygen Consumption in Patients with Chronic Heart Failure,’ J Exerc Sci Fit, 10(1):23-7. [cited by applicant]
Latini R et al., (2007), ‘Prognostic Value of Very Low Plasma Concentrations of Troponin Tin Patients with Stable Chronic Heart Failure,’ Circulation, 116(11):1242-9. [cited by applicant]
Inui, “Cancer anorexia-cachexia syndrome: current issues in research and management.” Cancer J Clin. Mar.-Apr. 2002;52(2):72-91. [cited by applicant]
Lokireddy et al., “Myostatin is a novel tumoral factor that induces cancer cachexia.” Biochem J. Aug. 15, 2012;446(1):23-36. [cited by applicant]
Lonberg N, (2008), ‘Fully Human Antibodies from Transgenic Mouse and Phage Display Platforms,’ Curr Opin Immunol, 20(4):450-9. [cited by applicant]
Lord et al. (2010, J. Small Animal Practice 51:210-218). [cited by applicant]
Marino et al., “The therapeutic potential of blocking the activin signalling pathway.” Cytokine Growth Factor Rev. Oct. 2013;24(5):477-84. [cited by applicant]
Matthys and Billiau, “Cytokines and cachexia.” Nutrition. Sep. 1997;13(9):763-70. [cited by applicant]
Meczekalski B et al., (2013), ‘Long-Term Consequences of Anorexia Nervosa,’ Maturitas, 75(3):215-20. [cited by applicant]
Mohler et al., “Nonsteroidal Selective Androgen Receptor Modulators (SARMs): Dissociating the Anabolic and Androgenic Activities of the Androgen Receptor for Therapeutic Benfit.” J. Med.Chem. 2008;52(12):3597-3617. [cited by applicant]
Morales FJ et al., (1999), ‘A Shuttle Walk Test for Assessment of Functional Capacity in Chronic Heart Failure,’ Am Heart J, 138(2 Pt 1):291-8. [cited by applicant]
Muscaritoli et al., Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) ‘cachexia-anorexia in chronic wasting diseases’ and ‘nutrition in geriatrics.… [cited by applicant]
Nagata et al., “Design and synthesis of tricyclic tetrahydroquinolines as a new series of nonsteroidal selective androgen receptor modulators (SARMs).” Bioorg. Med. Chem. Lett. 2011;21:1744-1747. [cited by applicant]
Ng et al., Synthesis of potent and tissue-selective androgen receptor modulators (SARMs): 2-(2,2,2)-Trifluoroethyl-benzimidazole scaffold. Bioorg Med Chem Lett. Mar. 15, 2007;17(6):1784-7. [cited by applicant]
Olson et al. (2007, J. Cardiac Failure 13(2):100-107). [cited by applicant]
Peterson, “Pressure Overload Hypertrophy and Congestive Heart Failure: Where is the ‘Achilles’ Heel?” J. Am. Coll. Cardiol., 2002;39(4):672-675. [cited by applicant]
Prado et al., “Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma.” Br J Cancer. May 8, 2012;106(10):1583-6. [cited by applicant]
Pulz C et al., (2008), ‘Incremental Shuttle and Six-Minute Walking Tests in the Assessment of Functional Capacity in Chronic Heart Failure,’ Can J Cardiol, 24(2):131-5. [cited by applicant]
Riiegg and Glass, “Molecular mechanisms and treatment options for muscle wasting diseases.” Annu Rev Pharmacol Toxicol. 2011;51:373-95. [cited by applicant]
Romano C et al., (2003), ‘Reduced Hemodynamic Load and Cardiac Hypotrophy in Patients with Anorexia Nervosa,’ Am J Clin Nutr, 77(2):308-12. [cited by applicant]
Romano et al., “Reduced hemodynamic load and cardiac hypotrophy in patients with anorexia nervosa,” Am J Clin Nutr. 2003;77(2):308-312. [cited by applicant]
Roth et al., “GDF-15 contributes to proliferation and immune escape of malignant gliomas,” Clin Cancer Res. Aug. 1, 2010;16(15):3851-9. [cited by applicant]
Sharma et al., “Molecular targets of cancer cachexia: opportunities for pharmanutritional approaches.” PharmaNutrition. 2013 <http://dx.doi.oro/10.1016/i.ohanu.2013.07.002>. [cited by applicant]
Springer et al. “Prevention of liver cancer cachexia-induced cardiac wasting and heart failure,” European Heart Journal 2014;35:932-941. [cited by applicant]
Steinman and DeBoer, “Chapter 8: Treatment of Cachexia: Melanocortin and Ghrelin Interventions.” Vitamins and Hormones. 2013; 92:197-240. [cited by applicant]
Stewart-Coats et al., “The ACT-ONE trial, a multicentre, randomised, double-blind, placebocontrolled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects cachexia related to stage III and… [cited by applicant]
Strassmann et al., Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor. J Immunol. Mar. 15, 1993;150(6):2341-5. [cited by applicant]
Strunk A et al., (2006), ‘Impact of the History of Congestive Heart Failure on the Utility of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure: Results from the Breathing Not Properly Multinational… [cited by applicant]
Sutton et al. (2003, Circulation 107(15):1985-1990). [cited by applicant]
Temel et al., “Efficacy and safety results from a phase II study of anamorelin HCI, a ghrelin receptor agonist, in NSCLC patients.” J. Cachexia Sarcopenia Muscle 2013;4:295-343 Abstract 5-01 from 7th Cachexia Conference… [cited by applicant]
Thomas, “Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia.” Clin Nutr. Aug. 2007;26(4):389-99. [cited by applicant]
Tisdale, “Cachexia in cancer patients.” Nat Rev Cancer. Nov. 2002;2(11):862-71. [cited by applicant]
Tobin JF and Celeste AJ, (2006), ‘Bone Morphogenetic Proteins and Growth Differentiation Factors as Drug Targets in Cardiovascular and Metabolic Disease,’ Drug Discov Today, 11(9-10):405-11. [cited by applicant]
Tsai et al., “Anorexia/cachexia of chronic diseases: a role for the TGF-13 family cytokine MIC-1/GDF15.” J Cachexia Sarcopenia Muscle. Dec. 2012;3(4):239-43. [cited by applicant]
Tsai VW-Wet al., (2013), ‘TGFb Superfamily Cytokine MIC-1/GDF15 is a Physiological Appetite and Body Weight Regulator,’ PLOSone, 8(2):e55174 (10 pages). [cited by applicant]
Tuca et al., “Clinical evaluation and optimal management of cancer cachexia.” Crit Rev Oncol Hematol. Dec. 2013;88(3):625-36. [cited by applicant]
Wallentin L et al., (2013), ‘GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men,’ PLoS One, 8(12):e78797. [cited by applicant]
Wallentin LC et al., (2013), ‘GDF-15 Level in Acute Coronary Syndrome and its Relations to Cardiovascular Risk Factors, Disease Manifestations, Treatments and Outcome—Results from the PLATO-Study,’ Eur Heart J, 34(Suppl… [cited by applicant]
Wilson JR et al., (1995), ‘Dissociation Between Peak Exercise Oxygen Consumption and Hemodynamic Dysfunction in Potential Heart Transplant Candidates,’ J Am Coll Cardiol, 26(2):429-35. [cited by applicant]
Winter et al., (1993), “Humanized antibodies,” Trends Pharmacol Sci., 14:139-43. [cited by applicant]
Wollert KC and Kempf T, (2012), ‘Growth Differentiation Factor 15 in Heart Failure: An Update,’ Curr Heart Fail Rep, 9(4):337-45. [cited by applicant]
Written Opinion of the International Searching Authority (Form ISA/237) for Intentional Application No. PCT/US2015/036790 mailed Nov. 30, 2015 (8 pages). [cited by applicant]
Xu, Jian et al. “GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation.” Circulation research vol. 98,3 (2006): 342-50. [cited by applicant]
Zhang et al., “Serendipitous discovery of novel imidazolopyrazole scaffold as selective androgen receptor modulators.” Bioorg Med Chem Lett. Jan. 15, 2007;17(2):439-43. [cited by applicant]
Zhang et al., “Synthesis and SAR of novel hydantoin derivatives as selective androgen receptor modulators.” Bioorg Med Chem Lett. Nov. 15, 2006;16(22):5763-6. [cited by applicant]
Zhou et al., “Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.” Cell. Aug. 20, 2010;142(4):531-43. [cited by applicant]